Cefazolin

Quick links to important sections

Cefazolin

Selected form

Method of action: Bactericidal

Treatment option:

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Cefazolin

Cefazolin Quick Facts

Property Description
Active ingredient Cefazolin Sodium
Form Sterile powder for injection (lyophilized product)
Pharmacological class First-generation cephalosporin, Beta-lactam antibiotic
Common use Systemic infection treatment, Surgical prophylaxis
Origin Semi-synthetic (derivative of 7-aminocephalosporanic acid)

What Type of Antibiotic is Cefazolin?

Cefazolin is a semi-synthetic antibiotic classified as a First-generation cephalosporin, which belongs to the broader beta-lactam antibiotic family. The active substance is Cefazolin Sodium, a compound derived from 7-aminocephalosporanic acid, establishing its specific identity within the extensive antibiotic class. This classification as a first-generation agent is clinically recognized for its reliability and established record in antimicrobial therapy, confirming its foundational role in medicine.


Formulation and General Purpose

Cefazolin is typically prepared as a sterile powder for injection, which is reconstituted into an injectable formulation intended for parenteral administration. The drug functions as a powerful bactericidal agent, meaning its general purpose is to directly kill susceptible bacteria throughout the body. Due to this effective and decisive action, it is routinely used by healthcare professionals to manage systemic infection treatment and for pre-emptive surgical prophylaxis—preventing infections before they can occur in high-risk settings.


How Cefazolin Differs from Other Common Antibiotics

Cefazolin’s primary differentiation lies in its specific target profile and administrative route compared to many newer or oral antibiotics. As a First-generation cephalosporin, it demonstrates reliable and potent activity against common Gram-positive bacteria that often cause serious infections. Cefazolin is a preferred agent for prophylaxis in surgical patients due to its established efficacy and favorable profile. Its required parenteral administration also distinguishes it from commonly prescribed oral antibiotics, ensuring its use in settings where rapid, complete, and predictable drug concentration is medically necessary for efficacy.

What side effects are possible with Cefazolin?

Possible Side Effects and Safety Information

Cefazolin is a cephalosporin class antibiotic. Its use is associated with several documented side effects and serious safety considerations, primarily related to hypersensitivity and gastrointestinal issues.

Adverse Reactions

The most common adverse reactions reported include gastrointestinal effects (such as nausea, vomiting, and diarrhea) and general allergic reactions (e.g., skin rash, urticaria).

Other adverse reactions that have been reported across various body systems include:

  • Hematologic: Transient changes such as eosinophilia, leukopenia, neutropenia, and thrombocytopenia.
  • Hepatic/Renal: Elevations in liver enzymes (SGOT, SGPT, alkaline phosphatase), increased blood urea nitrogen (BUN) and creatinine, and reports of renal failure.
  • Local: Pain, induration, or phlebitis at the injection site.
  • Nervous System: Headaches, dizziness, and, rarely, seizures.

Serious Safety Considerations

1. Hypersensitivity Reactions

Serious and sometimes fatal anaphylactic reactions have been documented with beta-lactam antibiotics, including Cefazolin. The drug is contraindicated in individuals with a known history of immediate hypersensitivity to Cefazolin, cephalosporins, penicillins, or other beta-lactams. Cross-sensitivity to Cefazolin may occur in up to 10% of patients who have a history of penicillin allergy.

2. Clostridioides difficile-Associated Diarrhea (CDAD)

CDAD may occur with the use of nearly all antibacterial agents, including Cefazolin. The severity of this condition can range from mild diarrhea to fatal colitis, and it may develop during or after the cessation of treatment.

Specific Safety Populations

  • Renal Impairment: Patients with reduced kidney function are at a higher risk for adverse effects, including the potential for seizures, and require dosage adjustment.
  • Prothrombin Activity: Cefazolin may be associated with a fall in prothrombin activity, particularly in at-risk patients, and monitoring may be necessary.

Overdose and Emergency Response

Overdose and When to Seek Help

Official regulatory information describes specific signs and actions required in the event of a Cefazolin overdose. The primary concern is the potential for Central Nervous System (CNS) manifestations, particularly the occurrence of seizures (convulsions), which are documented in association with inappropriately high doses.


Documented Overdose Risk Factors and Outcomes

Domain Official Regulatory Statement
Documented Manifestation Seizures are the principal neurological event documented with high doses.
Population-Specific Risk Patients with impaired renal function are at a heightened risk of developing seizures following high doses.
Life-Threatening Signs Severe outcomes that mandate immediate help include collapse, trouble breathing, or the inability to be awakened.

Required Emergency Actions

Immediate medical attention is required if any signs of severe overdose occur. The official guidance instructs that for life-threatening events, emergency services (911) must be contacted immediately. Additionally, individuals are directed to call the Poison Control Helpline for specific guidance on overdose management.

There is no specific chemical antidote documented in the prescribing information for Cefazolin overdose. Management, therefore, centers on symptomatic and supportive treatment. Procedural steps such as hemodialysis or peritoneal dialysis may be employed to aid in the removal of Cefazolin from the circulation in severe cases.

Therapeutic Uses of Cefazolin

What Cefazolin Treats: Main Uses and Benefits

Cefazolin is commonly used in important therapeutic contexts to address bacterial invasion and its associated distress. The medication is prescribed for treating infections caused by susceptible bacteria, and it is also used around the time of surgery to prevent infection. The therapeutic benefit contributes to easing the overall symptom load and supports general well-being during symptomatic phases.


Treating Severe Infections and Supporting Recovery

Cefazolin is considered relevant in situations where symptoms related to systemic imbalance are pronounced, such as high fever and malaise in conditions associated with severe infections. These conditions often involve symptomatic clusters of systemic discomfort, such as septicemia (blood infections), certain forms of pneumonia, deep-seated bone and joint infections, and infections of the skin and soft tissue. Its use helps address groups of symptoms that may appear suddenly and create noticeable physiological strain, and may assist with the temporary stabilization of functional comfort during acute, disruptive episodes.

Localized Comfort and Prevention

The medication is also applied in addressing localized infections like cellulitis and specific infections of the urinary or biliary tract, and may assist with easing pain and swelling. Furthermore, Cefazolin is considered relevant for surgical prophylaxis, commonly used in high-risk procedures (e.g., cardiac or orthopedic surgery) to help manage the risk of postoperative infection. This preventive use provides supportive relief that helps patients cope more steadily with the recovery process.


Quick Fact: Relief for Acute Distress
Cefazolin supports the patient by managing symptoms associated with acute bacterial disease, such as high fever and localized inflammation.

Regulatory References

  1. NIH MedlinePlus overview

Eligibility and Restrictions for Use

Eligibility and Contraindications for Cefazolin

Cefazolin’s eligibility is strictly defined by regulatory authorities based on a patient’s hypersensitivity status, age, and existing physiological conditions.

Contraindicated Populations

Cefazolin is contraindicated and must not be used by any patient with a known history of immediate hypersensitivity or severe allergic reaction to the active drug, the cephalosporin class of antibiotics, or related beta-lactam antibacterial agents such as penicillins.

Age-Group Eligibility

The medicine is established for use in adult patients and pediatric patients 1 month of age and older. Safety and effectiveness have not been established for premature infants and neonates (infants under 1 month of age).

Conditional Use and Restrictions

Use is conditional on certain physiological states. Patients with impaired renal function (Creatinine Clearance < 55 mL/min) are eligible, but the official label mandates dosage modification. The use of specific Cefazolin formulations containing dextrose may be restricted for individuals with Diabetes Mellitus or carbohydrate intolerance.

For pregnancy, Cefazolin is classified as Pregnancy Category B, but safety in human pregnancy has not been established. Administration to nursing mothers should proceed with caution, as low concentrations of the drug are detectable in breast milk.

What should I know about interactions with other medicines?

Cefazolin, like other cephalosporin antibiotics, may interact with specific medications or classes of products, primarily affecting drug levels and increasing the risk of certain side effects. It is important to inform a healthcare provider of all medicines, supplements, and vaccines being taken to safely manage any potential interactions.

Pharmacokinetic Interaction

  • Probenecid: Co-administration of the uricosuric agent probenecid with Cefazolin is a well-documented pharmacokinetic interaction. Probenecid inhibits the renal tubular secretion of Cefazolin. This competitive inhibition results in increased and prolonged serum concentrations of Cefazolin in the bloodstream.

Increased Risk of Bleeding

  • Anticoagulants: Concomitant use with blood-thinning medicines, such as warfarin, may increase the risk of bleeding. Close monitoring of blood clotting parameters is advised when Cefazolin is used alongside these products.

Impact on Vaccines

  • Live Bacterial Vaccines: Cefazolin may diminish the therapeutic effect of certain live bacterial vaccines, such as Typhoid Vaccine Live and Cholera Vaccine Live. It is generally advised to complete the course of the antibiotic treatment before receiving these types of vaccines. This is due to a risk of pharmacodynamic antagonism where the antibiotic may counteract the effect of the vaccine's live bacteria component.

Mechanism of Action

How Cefazolin Works

Cefazolin functions by selectively targeting the machinery responsible for building and maintaining the structural integrity of the bacterial cell wall, resulting in the lysis and death of susceptible bacterial cells.


Irreversible Inactivation of Cell Wall Enzymes

The drug’s core mechanism is its covalent inhibition of bacterial enzymes known as Penicillin-Binding Proteins ( PBPs), which are required for bacterial survival and structural integrity. Cefazolin binds permanently to the active site of these enzymes, immediately halting their function. This act of irreversible enzyme inhibition is the initial molecular interaction that begins the chain of cell wall degradation.


Structural Failure via Peptidoglycan Disruption

By inactivating the PBPs, Cefazolin prevents the essential cross-linking of peptidoglycan strands, the key structural component of the bacterial cell wall. This results in a structurally defective and weakened cell envelope that cannot withstand the high internal osmotic pressure. This structural failure, coupled with the activation of the bacterial cell's own Autolytic Enzymes, leads directly to rapid cell lysis (rupture) and a resulting bactericidal action.


Limitations Due to Target Modification

The drug’s mechanism is constrained when bacteria produce specific enzymes, such as beta-Lactamase, which chemically destroy Cefazolin before it can reach its target. Furthermore, genetic alterations or mutations of the PBP target reduce Cefazolin's binding affinity, limiting the effectiveness of its core inhibitory mechanism.

Dosage and Administration Information

Cefazolin is administered via parenteral routes, primarily through intravenous (IV) infusion or, less commonly, intramuscular (IM) injection. The medicine is typically supplied as a sterile powder that requires reconstitution with an appropriate diluent and subsequent dilution to prepare the solution for IV administration. Intravenous infusions are typically administered over a controlled duration of approximately 30 minutes.

The standard dosing regimens are structured based on the specific clinical context. For the treatment of established infections in adults with normal kidney function, doses range from 250 mg to 1.5 grams per administration, delivered in divided schedules of every 6, 8, or 12 hours. The total daily dose for severe, life-threatening infections is documented to be up to 12 grams.

For surgical prophylaxis, Cefazolin is administered as a dose of 1 to 2 grams and must be timed specifically, given 1/2 hour to 1 hour prior to the commencement of the procedure. The overall prophylactic course is typically discontinued within 24 hours post-surgery.

A mandatory procedural requirement is the adjustment of dosage and interval for adult patients with renal impairment. The required frequency and dose are modified based on the patient's measured Creatinine Clearance (CrCl) to ensure appropriate administration of the medicine.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Cefazolin

Evidence for Preventing Postoperative Infections (Surgical Prophylaxis)

Research exploring Cefazolin's use for surgical prophylaxis has largely relied on a foundation of Randomized Controlled Trials (RCTs) and comprehensive Systematic Reviews. These studies monitor outcomes related to systemic or functional imbalance, focusing on whether the use of the compound during the procedure influences the subsequent occurrence of post-surgical infections. The research was conducted across populations of adult patients undergoing various surgical procedures, including high-risk procedures like orthopedic (bone/joint) and cardiac operations.

Studies monitored the incidence of Surgical Site Infection (SSI), which is one of the outcomes related to physical discomfort that researchers tracked over defined time intervals. Findings describe patterns observed in these studies regarding the occurrence of infection in the 30 to 90 days following a procedure. The body of research, according to official regulatory summaries, includes data patterns observed over decades of studies. However, the evidence is limited in that some foundational RCTs are older and do not always reflect modern surgical techniques.


Evidence for Treating Serious Systemic Infections

The evidence for Cefazolin's role in treating serious systemic infections, such as bloodstream infections (septicemia) and deep-seated conditions like bone or heart valve infections, often relies on Systematic Reviews and Observational Cohort Studies. These studies explored outcomes describing episodic or acute changes and monitored mortality and relapse rates in patients with infections caused by Methicillin-Susceptible Staphylococcus aureus (MSSA).

Studies examined patient outcomes when Cefazolin was compared in cohorts receiving other treatments. Research highlights changes measured during the study period related to clinical cure and infection recurrence. A key area of scientific uncertainty relates to the Cefazolin Inoculum Effect (CzIE), a laboratory phenomenon. Research examined whether MSSA isolates that display this effect in vitro were associated with worse outcomes for patients with deep-seated infections. Findings related to the CzIE were mixed across small, observational studies, and data are still emerging. Consequently, the clinical significance of this effect remains uncertain.


Understanding Research Gaps and Uncertainty

While Cefazolin is a well-established medication with a significant body of evidence, research highlights what is known and what is still uncertain. Follow-up durations were often limited across many studies. There is limited information for long-term outcomes, such as sustained functional comfort or durability of effect, after the initial acute phase of treatment has ended.

Frequently Asked Questions (FAQ)

Common questions about Cefazolin (FAQ)

Q: How quickly does Cefazolin start working after it's given?

A: Studies indicate that after being given intravenously, Cefazolin's serum concentrations (the amount in the bloodstream) are measurable relatively quickly, with the serum half-life being approximately 1.8 hours. Official data also show that the concentration of the medicine in specific body fluids, such as synovial fluid (found in joints), becomes similar to the blood concentration about four hours after administration.

Q: What is the difference between Cefazolin and Cephalexin?

A: Official classifications categorize both Cefazolin and Cephalexin as First-generation cephalosporin antibiotics. A key difference noted in regulatory context is that Cefazolin is a compound administered by injection (parenterally) while Cephalexin is an oral formulation.

Q: Is Cefazolin safe for people who are allergic to penicillin?

A: The medicine is generally contraindicated (not recommended for use) if a patient has a known history of a severe allergic reaction to cephalosporin, penicillin, or other beta-lactam antibiotics. The prescribing information notes that there is a risk of cross-sensitivity (an allergy to one causes a reaction to the other) for patients who have had a reaction to penicillin.

Q: Does Cefazolin interact with common pain relievers?

A: Regulatory documents prioritize interactions that affect the drug’s concentration or increase the risk of bleeding, such as with warfarin or probenecid. No specific interaction with common, non-prescription pain relievers (like ibuprofen or acetaminophen) is typically highlighted as a major warning requiring dosage change in the product information.

Q: Can you drink alcohol while being treated with Cefazolin?

A: Cefazolin is listed as a medicine that may potentially cause a disulfiram-like reaction when consumed with alcohol. This type of reaction can cause unpleasant effects such as facial flushing, rapid heartbeat, or nausea. Patients are advised to be cautious.

Q: Does Cefazolin affect birth control pills?

A: Regulatory information indicates that antibiotics, including Cefazolin, may reduce the effectiveness of certain birth control pills that contain estrogen. This potential interaction may result in a reduced effect of the contraceptive, which could be associated with an increased risk of pregnancy or breakthrough bleeding.

Q: How long after the last dose will Cefazolin be fully out of my system?

A: The medicine is primarily removed from the body by the kidneys, with studies showing that approximately 70% to 80% of the drug is eliminated within 24 hours after the dose is given. The drug's serum half-life (the time it takes for the concentration to reduce by half) is about 1.8 hours.

Q: Can Cefazolin cause confusion or mental changes?

A: The official adverse reaction lists include effects on the Nervous System, such as headaches, dizziness, and, rarely, seizures. While confusion or broader mental changes are not always specifically detailed, these reported CNS effects suggest a potential for altered neurological function.

Q: How is Cefazolin stored before it is prepared for use?

A: The official product labeling states that the Cefazolin unreconstituted powder must be stored at a controlled room temperature (between 20 C and 25 C or 68 F and 77 F). It should also be protected from light and kept in the original container until it is prepared by a healthcare professional.

Q: Does Cefazolin cause stomach upset or diarrhea?

A: Official prescribing information documents gastrointestinal effects as among the most common adverse reactions reported by users. These effects include nausea, vomiting, and diarrhea.

Q: What should be avoided when taking Cefazolin?

A: Cefazolin is not recommended for use if there is a known history of a serious allergy to Cefazolin or related antibiotics. Additionally, caution is advised when co-administering the drug with Probenecid (a drug that can increase Cefazolin levels), anticoagulants (due to increased bleeding risk), and certain live bacterial vaccines (due to reduced vaccine effectiveness).

Q: Are there any major diet restrictions when using Cefazolin?

A: Official prescribing information does not list specific food or major diet restrictions that impact the function of Cefazolin. However, it is noted that specific formulations (e.g., those containing dextrose) may require careful consideration for patients with conditions like Diabetes Mellitus.

Q: What is the main purpose of Cefazolin in a hospital setting?

A: According to official documents, Cefazolin is used for the treatment of moderate to severe systemic infections caused by susceptible bacteria. It is also widely used by healthcare professionals for surgical prophylaxis, which is the prevention of infection before and during high-risk surgical procedures.

Q: Can Cefazolin affect blood sugar levels?

A: Official product information states that Cefazolin may affect the results of certain laboratory tests, specifically tests used to check for glucose in the urine. Patients with high blood sugar (diabetes) who use older copper reduction methods to test their urine glucose should consult their healthcare provider for advice on reliable alternative tests.

Q: Is Cefazolin a broad-spectrum or narrow-spectrum antibiotic?

A: The World Health Organization (WHO) and other regulatory systems list Cefazolin as an Access antibiotic, which generally indicates a narrower spectrum of activity appropriate for common bacterial types. This classification is based on its established profile in antimicrobial therapy.

Q: What is the general duration of treatment with Cefazolin?

A: For surgical prophylaxis (prevention), official instructions usually state that the course is discontinued within 24 hours after the surgery. For the treatment of established infections (e.g., bone or joint infections), the duration is highly dependent on the type and severity of the condition and is determined solely by the treating healthcare professional.

Q: Can Cefazolin be used for urinary tract infections (UTIs)?

A: Official regulatory indications confirm that Cefazolin is approved for the treatment of certain Urinary Tract Infections (UTIs) that are caused by bacteria known to be susceptible to the medicine.

Q: Is Cefazolin commonly used for dental infections?

A: Cefazolin's approved indications include the treatment of skin and soft tissue infections and bone and joint infections. While not a primary, specific indication, its use has been supported in various protocols for infections involving the soft tissue or bone structure caused by susceptible organisms.

Q: What is the risk of a severe allergic reaction to Cefazolin?

A: The official prescribing information for Cefazolin strongly warns that serious, life-threatening, and sometimes fatal anaphylactic reactions have been documented with beta-lactam antibiotics. The risk is considered high enough that the drug is contraindicated (should not be used) in patients with a history of known hypersensitivity.

Q: Does Cefazolin have a generic name?

A: Yes, Cefazolin itself is the generic name for the active drug. The medicine is sometimes referred to in official documents as Cefazolin Sodium, which is the chemical form of the sterile powder used for injection.

Q: Can Cefazolin affect the results of any laboratory tests?

A: Yes, regulatory documents indicate that Cefazolin may cause a false-positive reaction for glucose in the urine when using older, specific testing methods (copper reduction tests). Additionally, it has been associated with transient changes in some blood cell counts, such as those found in hematologic (blood) tests.

Q: What if I miss a scheduled dose of Cefazolin (non-directive)?

A: Official administration instructions emphasize the importance of strict adherence to the dosing schedule prescribed by the healthcare provider. The course of action required for a missed dose is not standardized and must be determined by the prescriber based on the specific condition being treated and the treatment regimen in place.

Q: Is Cefazolin only for hospital use, or can it be given elsewhere?

A: While Cefazolin is most often used in a hospital due to its requirement for parenteral administration (IV or IM injection), studies have supported its use for necessary prolonged antibiotic therapy on an outpatient basis. This may be facilitated through home health services or specialized infusion centers.

Q: Can Cefazolin be used for respiratory tract infections?

A: Yes, official regulatory indications confirm that Cefazolin is approved for the treatment of certain Respiratory Tract Infections that are caused by bacteria known to be susceptible to the medicine, including specific forms of pneumonia.

Q: What is the evidence regarding Cefazolin use in the elderly?

A: Official prescribing information does not list unique dosing requirements specifically for geriatric patients. However, it does mandate a dosage adjustment for renal impairment (reduced kidney function), a condition that is often more prevalent in the elderly population and requires careful consideration when Cefazolin is administered.

Q: Are there known interactions between Cefazolin and herbal supplements?

A: The official drug labeling does not list specific herbal supplements that interact with Cefazolin. However, regulatory bodies advise caution generally, recommending that patients inform their healthcare provider of all medicines, supplements, or herbal products being used to safely manage potential interactions.

Q: Can Cefazolin be used to prevent infection after a bite?

A: While not a primary, specific indication, Cefazolin's use in the prevention of infection following trauma, such as certain open fractures, is consistent with its role in prophylaxis for infections involving the skin, soft tissue, and bone.

How should Cefazolin be stored and disposed of?

How to Store and Dispose of Cefazolin

The storage requirements for Cefazolin (sterile powder for injection) depend on the product's state, as defined by official regulatory labeling.

Storage Conditions

Product State Temperature & Protection Stability Limit
Unreconstituted Powder Controlled room temperature (20 C to 25 C); Protect from light; Store in original container. Shelf life before reconstitution
Reconstituted Solution Room temperature (25 C) or Refrigerated (5 C) 24 hours (Room Temp) or 96 hours (Refrigerated)

Handling and Disposal

The medicine must be stored strictly out of the sight and reach of children.

Any unused Cefazolin, including expired product or waste materials, must be disposed of in accordance with local requirements. The official prescribing information advises consulting local drug take-back programs or waste management centers for proper guidance on discarding medication.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Cefazolin found in:

A-Z Index: